MICROSAIC SYSTEMS PLC

Report Publication Announcement • Sep 4, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1079L

Microsaic Systems plc

04 September 2019

4 September 2019

Microsaic Systems plc

("Microsaic", "Microsaic Systems" or the "Company")

Notice of Results

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, will announce its results for the six months to 30 June 2019 on Monday 23 September 2019.

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD	+44 (0) 1483 751 577
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson Tom Salvesen	+44 (0)20 7496 3000
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler	+44 (0)20 3934 6630

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORLLFLRAFIVIIA